Features of treatment of patients with psoriasis with metabolic syndrome
The article provides information on the prevalence of metabolic syndrome in patients with psoriasis. The criteria for the diagnosis of metabolic syndrome are presented. The General mechanisms of inflam - mation development in psoriasis and diseases forming the metabolic syndrome are described. Syste...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
State Scientific Center of Dermatovenereology and Cosmetology
2018-12-01
|
| Series: | Vestnik Dermatologii i Venerologii |
| Subjects: | |
| Online Access: | https://www.vestnikdv.ru/jour/article/view/426 |
| Summary: | The article provides information on the prevalence of metabolic syndrome in patients with psoriasis. The criteria for the diagnosis of metabolic syndrome are presented. The General mechanisms of inflam - mation development in psoriasis and diseases forming the metabolic syndrome are described. Systemic subclinical inflammatory process developing in psoriasis and metabolic syndrome is considered as the main pathogenetic mechanism of their mutual negative influence. The difficulties of treatment of patients with psoriasis with metabolic syndrome are largely associated with the choice of a safe and effective method of treatment. The description of the drug apremilast (OTEZLA®) is a selective inhibitor of the enzyme phosphodiesterase 4, which may be the best drug in the therapy of patients with psoriasis and metabolic syndrome. |
|---|---|
| ISSN: | 0042-4609 2313-6294 |